Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Feb;10(5):e018574.
doi: 10.1161/JAHA.120.018574. Epub 2021 Feb 23.

Sex Differences in Heart Failure With Preserved Ejection Fraction

Affiliations
Observational Study

Sex Differences in Heart Failure With Preserved Ejection Fraction

Yohei Sotomi et al. J Am Heart Assoc. 2021 Feb.

Abstract

Background The female preponderance in heart failure with preserved ejection fraction (HFpEF) is a distinguishing feature of this disorder, but the association of sex with degree of diastolic dysfunction and clinical outcomes among individuals with HFpEF remains unclear. Methods and Results We conducted a prospective, multicenter, observational study of patients with HFpEF (PURSUIT-HFpEF [Prospective Multicenter Observational Study of Patients with Heart Failure with Preserved Ejection Fraction]: UMIN000021831). Between 2016 and 2019, 871 patients were enrolled from 26 hospitals (follow-up: 399±349 days). We investigated sex-related differences in diastolic dysfunction and postdischarge clinical outcomes in patients with HFpEF. The echocardiographic end point was diastolic dysfunction according to American Society of Echocardiography/European Association of Cardiovascular Imaging criteria. The clinical end point was a composite of all-cause death and heart failure readmission. Women accounted for 55.2% (481 patients) of the overall cohort. Compared with men, women were older and had lower prevalence rates of hypertension, coronary artery disease, and chronic kidney disease. Women had diastolic dysfunction more frequently than men (52.8% versus 32.0%, P<0.001). The incidence of the clinical end point did not differ between women and men (women 36.1/100 person-years versus men 30.5/100 person-years, P=0.336). Female sex was independently associated with the echocardiographic end point (adjusted odds ratio, 2.839; 95% CI, 1.884-4.278; P<0.001) and the clinical end point (adjusted hazard ratio, 1.538; 95% CI, 1.143-2.070; P=0.004). Conclusions Female sex was independently associated with the presence of diastolic dysfunction and worse clinical outcomes in a cohort of elderly patients with HFpEF. Our results suggest that a sex-specific approach is key to investigating the pathophysiology of HFpEF. Registration URL: https://upload.umin.ac.jp; Unique identifier: UMIN000021831.

Keywords: diastolic dysfunction; heart failure; preserved left ventricular function; prognosis; sex.

PubMed Disclaimer

Conflict of interest statement

Y. Sotomi received personal fees from Daiichi‐Sankyo, Bayer, Boehringer Ingelheim, and Bristol‐Myers Squibb. S. Hikoso received grants from Roche Diagnostics, FUJIFILM Toyama Chemical, Actelion Pharmaceuticals; personal fees from Daiichi Sankyo, Astellas Pharma, Bayer, Pfizer Pharmaceuticals, Boehringer Ingelheim Japan, Kowa Company, and Ono Pharmaceutical. D. Nakatani received personal fees from Roche Diagnostics. H. Mizuno is an endowed chair lecturer supported by Asahi Intecc Co., Ltd, Terumo Corporation, Nipro Corporation and Shimadzu Corporation, and received personal fees from Medtronic Japan Co.,Ltd, Japan Tobacco Inc, Pfizer Japan Inc., Bayer Yakuhin, Ltd., Japan Lifeline Co.,Ltd, Abbott Japan LLC., Nippon Boehringer Ingelheim Co., Ltd, Toa Eiyo Ltd, Daiichi Sankyo Co., Ltd, and Kowa Co., Ltd. K. Okada received personal fees from Bayer. Y. Sakata received personal fees from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K. and Actelion Pharmaceuticals, and received grants form Roche Diagnostic, FUJIFILM Toyama Chemical, Bristol‐Myers Squibb, Co, Biosense Webster, Inc., Abbott Medical Japan, Otsuka Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma, Kowa Company, Boehringer Ingelheim Japan, and Biotronik. The remaining authors have no disclosures to report.

Figures

Figure 1
Figure 1. Comorbidities related to diastolic dysfunction in the overall cohort.
Multivariable binary logistic regression analysis was performed in order to assess the impact of multiple comorbidities on the echocardiographic end point (diastolic dysfunction) in the overall cohort (N=595). Results are illustrated as a forest plot. Female sex, anemia, and obesity were significant factors associated with diastolic dysfunction. OR indicates odds ratio.
Figure 2
Figure 2. Clinical outcomes stratified by sex.
A, The clinical end point of all‐cause death or heart failure readmission was assessed in a time‐to‐first‐event fashion with Kaplan–Meier analysis. In the crude comparison, no difference was found between women and men (log‐rank P=0.191). B, Adjusted probability curves in women and men created with the multivariable Cox proportional hazards model included the following covariates: female sex, C‐reactive protein, age, anemia (hemoglobin level <12 g/dL in women and <13 g/dL in men according to the World Health Organization definition 15 ), hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, chronic kidney disease, atrial fibrillation, obesity (body mass index ≥25), and cholinesterase level. 6 , 13 The cumulative probability curves show the model‐predicted event rates for the “average” patient in women and men. HF indicates heart failure; and HR, hazard ratio.
Figure 3
Figure 3. Prognostic factors for the clinical end point in the overall cohort.
A multivariable Cox proportional hazards model was constructed in order to assess the impact of multiple comorbidities on the postdischarge clinical end point in the overall cohort (N=870). The results are shown as a forest plot. Female sex, age, coronary artery disease, chronic kidney disease, and cholinesterase were significantly associated with the clinical end point. HR indicates hazard ratio.

References

    1. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. DOI: 10.1056/NEJMoa1409077. - DOI - PubMed
    1. Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, et al. Baseline features of the VICTORIA (vericiguat global study in subjects with heart failure with reduced ejection fraction) trial. Eur J Heart Fail. 2019;21:1596–1604. DOI: 10.1002/ejhf.1664. - DOI - PubMed
    1. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332–1342. DOI: 10.1056/NEJMoa1808848. - DOI - PubMed
    1. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–2467. DOI: 10.1056/NEJMoa0805450. - DOI - PubMed
    1. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392. DOI: 10.1056/NEJMoa1313731. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources